Three-month versus twelve-month dual antiplatelet therapy after acute coronary syndrome: An updated meta-analysis of randomized trials with trial sequential analysis.
BACKGROUND The optimal duration of dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) remains uncertain. Advances in stent design and the use of potent P2Y₁₂ inhibitors have reduced thrombotic risk, raising questions about whether prolonged DAPT co...